Dyne Therapeutics (NASDAQ:DYN) Given “Buy” Rating at Guggenheim

Guggenheim reiterated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a research note published on Friday morning,Benzinga reports.

A number of other analysts have also weighed in on the company. Robert W. Baird initiated coverage on Dyne Therapeutics in a research report on Friday, December 13th. They set an “outperform” rating and a $46.00 price objective on the stock. JPMorgan Chase & Co. downgraded Dyne Therapeutics from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $43.00 to $35.00 in a report on Thursday, October 24th. Raymond James upgraded Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Chardan Capital restated a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a research note on Friday, January 10th. Finally, Baird R W upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Dyne Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $49.91.

Dyne Therapeutics Price Performance

Shares of Dyne Therapeutics stock opened at $13.72 on Friday. The stock has a market capitalization of $1.40 billion, a price-to-earnings ratio of -3.85 and a beta of 1.16. The business has a 50-day moving average of $24.03 and a 200 day moving average of $32.63. Dyne Therapeutics has a 12 month low of $13.44 and a 12 month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.25). Equities research analysts anticipate that Dyne Therapeutics will post -3.44 earnings per share for the current year.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, Director Carlo Incerti sold 16,500 shares of Dyne Therapeutics stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $28.73, for a total transaction of $474,045.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Richard William Scalzo sold 1,455 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $40,914.60. Following the completion of the sale, the senior vice president now directly owns 127,078 shares of the company’s stock, valued at $3,573,433.36. The trade was a 1.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 21,071 shares of company stock valued at $606,476 over the last ninety days. Insiders own 20.77% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in DYN. Quantbot Technologies LP purchased a new position in shares of Dyne Therapeutics during the third quarter worth about $34,000. Point72 DIFC Ltd purchased a new position in shares of Dyne Therapeutics in the 3rd quarter valued at approximately $36,000. US Bancorp DE increased its holdings in shares of Dyne Therapeutics by 776.9% in the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after purchasing an additional 1,212 shares during the period. Values First Advisors Inc. purchased a new stake in shares of Dyne Therapeutics during the third quarter worth approximately $62,000. Finally, KBC Group NV lifted its holdings in shares of Dyne Therapeutics by 45.3% during the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after purchasing an additional 978 shares during the period. 96.68% of the stock is owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.